MAPT and Alzheimer disease: In the context of a structured 5-phase development framework of biomarkers for AD, the first- and second-generation tau PET tracers are currently considered at the clinical validity phase (Bischof et al., 2021; Chiotis et al., 2021; Wolters et al., 2021).